Transforming PRP into a Shelf-Stable therapy: Lyophilization preserves angiogenic and regenerative properties

Articles in Press

Document Type : Original Article

Authors

1 Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

2 Tissue Engineering Research Group, Department of Anatomy and Cell Biology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

3 Department of Medical Genetics & Molecular Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

4 Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

5 Hematopoietic Stem Cell Research Centre-Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

10.22038/ijbms.2026.93868.20236

Abstract

Objective(s): Platelet-rich plasma (PRP) is widely used in regenerative medicine due to its high concentration of bioactive growth factors; however, its short shelf life limits its clinical applicability. Lyophilization has been proposed to extend PRP stability, but its impact on biological efficacy remains unclear. This study evaluated whether lyophilization alters the biochemical composition and regenerative function of PRP derived from expired platelet units unsuitable for transfusion.
Materials and Methods: Pooled isogroup PRP was processed as either liquid PRP or lyophilized PRP. Growth factors (FGF-1, PDGF, VEGF) and endotoxin levels were quantified. Biological activity was assessed in human dermal fibroblasts (HDFs) and human umbilical vein endothelial cells (HUVECs) using MTT assays, in vitro wound closure, gene expression analysis (MMP-1, MMP-3, Ang1, PDGFR), and CD31 immunocytochemistry at 5% and 10% concentrations, with fetal bovine serum (FBS) as a control.
Results: Lyophilization resulted in moderate reductions in FGF-1, PDGF, and VEGF relative to Liquid-PRP (P<0.05), while endotoxin levels remained acceptable. In HDFs, liquid-PRP induced higher MMP-1 and MMP-3 expression, whereas lyophilized-PRP promoted lower but sufficient expression, consistent with controlled extracellular matrix remodeling, with comparable wound-closure outcomes between PRP groups. In HUVECs, lyophilized PRP preserved cell viability, migration, and CD31 expression, comparable to liquid PRP and FBS. Angiogenic gene expression showed a concentration-dependent response, with maximal activation at 5% PRP, and no functional impairment after lyophilization (P<0.05).
Conclusion: Despite a moderate reduction in growth factors, lyophilized PRP retained regenerative efficacy, supporting lyophilization as a viable strategy for the stable, sustainable reuse of PRP.

Keywords

Main Subjects

References

1. Shimizu Y, Ntege EH, Sunami H. Current regenerative medicine-based approaches for skin regeneration: A review of literature and a report on clinical applications in Japan. Regen Ther 2022; 21:73-80.
2. Gholipourmalekabadi M, Sapru S, Samadikuchaksaraei A, Reis RL, Kaplan DL, Kundu SC. Silk fibroin for skin injury repair: Where do things stand? Adv Drug Deliv Rev 2020; 153: 28-53.
3. Rahvar M, Manoochehrabadi T, Marouf BT, Lakalayeh GA, Kakolvand R, Habibi H, et al. Engineering micro/nanostructured biodegradable nanoclay-based nanocomposite coatings for sustained drug release and rapid endothelialization in drug-eluting stents. BioNanoScience 2026; 16: 90.
4. Manoochehrabadi T, Solouki A, Majidi J, Khosravimelal S, Lotfi E, Lin K, et al. Silk biomaterials for corneal tissue engineering: From research approaches to therapeutic potentials; A review. Int J Biol Macromol 2025; 305: 141039.
5. Daryabari S-H, Ghasemian M, Lotfi E, Solouki A, Lin K, Manoochehrabadi T, et al. Placental-derived products for corneal regeneration: applications of amniotic membrane, cord blood serum, and stem cells: A review. Transplant Cell Ther 2026; 32: 13-45.
6. Verma R, Kumar S, Garg P, Verma YK. Platelet-rich plasma: A comparative and economical therapy for wound healing and tissue regeneration. Cell Tissue Bank 2023; 24: 285-306.
7. Paichitrojjana A, Paichitrojjana A. Platelet rich plasma and its use in hair regrowth: A review. Drug Des Devel Ther 2022; 16: 635-645.
8. White C, Brahs A, Dorton D, Witfill K. Platelet-rich plasma: A comprehensive review of emerging applications in medical and aesthetic dermatology. J Clin Aesthet Dermatol 2021; 14: 44-57.
9. Beitia M, Delgado D, Mercader J, Gimeno I, Espregueira-Mendes J, Aizpurua B, et al. The effect of short-term cryopreservation on the properties and functionality of platelet-rich plasma. Platelets 2023; 34: 2210243.
10. Jonsdottir-Buch SM, Lieder R, Sigurjonsson OE. Platelet lysates produced from expired platelet concentrates support growth and osteogenic differentiation of mesenchymal stem cells. PLoS One 2013; 8: e68984.
11. da Silva LQ, Montalvão SAL, Justo-Junior ADS, Cunha Júnior JLR, Huber SC, Oliveira CC, et al. Platelet-rich plasma lyophilization enables growth factor preservation and functionality when compared with fresh platelet-rich plasma. Regen Med 2018; 13: 775-784.
12. Shiga Y, Kubota G, Orita S, Inage K, Kamoda H, Yamashita M, et al. Freeze-dried human platelet-rich plasma retains activation and growth factor expression after an eight-week preservation period. Asian Spine J 2017; 11: 329-336.
13. Manoochehrabadi T, Samadikuchaksaraei A, Solouki A, Daryabari S-H, Ghasemi H, Lotfi E, et al. Substrate engineering using naturally biomimicking corneal cell topography for preserving stemness of corneal limbal epithelial-stem cells. Iran J Basic Med Sci 2025; 28: 916-928.
14. Lotfi E, Kholghi A, Golab F, Mohammadi A, Barati M. Circulating miRNAs and lncRNAs serve as biomarkers for early colorectal cancer diagnosis. Pathol Res Pract 2024; 255: 155187.
15. Oeller M, Laner-Plamberger S, Krisch L, Rohde E, Strunk D, Schallmoser K. Human platelet lysate for good manufacturing practice-compliant cell production. Int J Mol Sci 2021; 22: 5178.
16. Schallmoser K, Henschler R, Gabriel C, Koh MB, Burnouf T. Production and quality requirements of human platelet lysate: A position statement from the working party on cellular therapies of the international society of blood transfusion. Trends Biotechnol 2020; 38: 13-23.
17. Hariprasad R, Suganya TL, John SS, Raj PR, Kuriakose F, Anoop VN. Assessment of growth factors with three different platelet preparations, namely platelet-rich fibrin, platelet-rich plasma, and lyophilized platelet: An in vitro study. J Pharm Bioallied Sci 2021; 13: S1696-s1699.
18. Silva LQd, Huber SC, Montalvão SADL, Bassora FDS, De Paula EV, Annichino-Bizzacchi J. Platelet activation is not crucial for platelet-rich plasma (PRP), when used as autologous therapeutic product, and could be lyophilized without any growth factor loss. Blood 2016; 128: 2639.
19. Chicharro-Alcántara D, Rubio-Zaragoza M, Damiá-Giménez E, Carrillo-Poveda JM, Cuervo-Serrato B, Peláez-Gorrea P, et al. Platelet rich plasma: New insights for cutaneous wound healing management. J Func Biomater 2018; 9: 10.
20. Chandra P, Faizan M, Porwal M, Sharma H, Sachan N. An overview and review of growth factors in wound healing: Emerging trends and innovations. Curr Diabetes Rev 2026; 22: 1-27.
21. Vaidyanathan L. Growth factors in wound healing—a review. Biomed Pharmacol J 2021; 14: 1469-1480.
22. Nazarnezhad S, Kermani F, Askari VR, Hosseini SA, Ebrahimzadeh-Bideskan A, Moradi A, et al. Preparation and characterization of platelet lysate (Pl)-loaded electrospun nanofibers for epidermal wound healing. J Pharm Sci 2022; 111: 2531-2539.
23. Saputro ID, Ardan AM, Yuniarti WM, Putra ON. The wound healing effect of allogeneic freeze-dried platelet-rich plasma in a full-thickness wound animal model. J Rep Pharm Sci 2021; 10: 71-76.
24. Karunnanithy V, Abdul Rahman NHB, Abdullah NAH, Fauzi MB, Lokanathan Y, Min Hwei AN, et al. Effectiveness of lyoprotectants in protein stabilization during lyophilization. Pharmaceutics 2024; 16: 1346.
25. Butreddy A, Janga KY, Ajjarapu S, Sarabu S, Dudhipala N. Instability of therapeutic proteins - An overview of stresses, stabilization mechanisms and analytical techniques involved in lyophilized proteins. Int J Biol Macromol 2021; 167: 309-325.
26. Valente S, Ciavarella C, Astolfi G, Bergantin E, Curti N, Buzzi M, et al. Impact of freeze-drying on cord blood (CB), serum (S), and platelet-rich plasma (CB-PRP) preparations on growth factor content and in vitro cell wound healing. Int J Mol Sci 2022; 23: 10701.
27. Notodihardjo SC, Morimoto N, Kakudo N, Mitsui T, Le TM, Tabata Y, et al. Comparison of the efficacy of cryopreserved human platelet lysate and refrigerated lyophilized human platelet lysate for wound healing. Regen Ther 2019; 10: 1-9.
28. Hara T, Kakudo N, Morimoto N, Ogawa T, Lai F, Kusumoto K. Platelet-rich plasma stimulates human dermal fibroblast proliferation via a Ras-dependent extracellular signal-regulated kinase 1/2 pathway. J Artif Organs 2016; 19: 372-377.
29. Devereaux J, Dargahi N, Fraser S, Nurgali K, Kiatos D, Apostolopoulos V. Leucocyte-rich platelet-rich plasma enhances fibroblast and extracellular matrix activity: Implications in wound healing. Int J Mol Sci 2020; 21: 6519.
30. Katz M, Amit I, Yarden Y. Regulation of MAPKs by growth factors and receptor tyrosine kinases. Biochim Biophys Acta 2007; 1773: 1161-1176.
31. Pufe T, Harde V, Petersen W, Goldring M, Tillmann B, Mentlein R. VEGF induces matrix metalloproteinase expression in chondrocytes. J Pathol 2004; 202: 367-374.
32. Shimazu A, Morishita M. Basic fibroblast growth factor induces the expression of matrix metalloproteinase-3 in human periodontal ligament cells through the MEK2 mitogen-activated protein kinase pathway. J Periodontal Res 2003; 38: 122-129.
33. Lazaro JL, Izzo V, Meaume S, Davies AH, Lobmann R, Uccioli L. Elevated levels of matrix metalloproteinases and chronic wound healing: an updated review of clinical evidence. J Wound Care 2016; 25: 277-287.
34. Gibson DJ, Schultz GS. Molecular wound assessments: Matrix metalloproteinases. Adv Wound Care (New Rochelle) 2013; 2: 18-23.
35. Bakadia BM, Qaed Ahmed AA, Lamboni L, Shi Z, Mutu Mukole B, Zheng R, et al. Engineering homologous platelet-rich plasma, platelet-rich plasma-derived exosomes, and mesenchymal stem cell-derived exosomes-based dual-crosslinked hydrogels as bioactive diabetic wound dressings. Bioact Mater 2023; 28: 74-94.
36. Cho EB, Park GS, Park SS, Jang YJ, Kim KH, Kim KJ, et al. Effect of platelet-rich plasma on proliferation and migration in human dermal fibroblasts. J Cosmet Dermatol 2019; 18: 1105-1112.
37. Yeung CY, Hsieh PS, Wei LG, Hsia LC, Dai LG, Fu KY, et al. Efficacy of lyophilised platelet-rich plasma powder on healing rate in patients with deep second degree burn injury: A prospective double-blind randomized clinical trial. Ann Plast Surg 2018; 80: S66-S69.
38. Bertrand-Duchesne MP, Grenier D, Gagnon G. Epidermal growth factor released from platelet-rich plasma promotes endothelial cell proliferation in vitro. J Periodontal Res 2010; 45: 87-93.
39. Kobayashi M, Kawase T, Okuda K, Wolff LF, Yoshie H. In vitro immunological and biological evaluations of the angiogenic potential of platelet-rich fibrin preparations: A standardized comparison with PRP preparations. Int J Implant Dent 2015; 1: 31.
40. Berndt S, Carpentier G, Turzi A, Borlat F, Cuendet M, Modarressi A. Angiogenesis is differentially modulated by platelet-derived products. Biomedicines 2021; 9: 251.
41. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.
42. Xu X, Pang Y, Fan X. Mitochondria in oxidative stress, inflammation and aging: from mechanisms to therapeutic advances. Signal Transduction and Targeted Therapy 2025; 10: 190.
43. Lee C, Kim M-J, Kumar A, Lee H-W, Yang Y, Kim Y. Vascular endothelial growth factor signaling in health and disease: From molecular mechanisms to therapeutic perspectives. Signal Transduct Targeted Ther 2025; 10: 170.
44. Dzięgielewska-Gęsiak S, Muc-Wierzgoń M. Inflammation and oxidative stress in frailty and metabolic syndromes-two sides of the same coin. Metabolites 2023; 13: 475.
45. Altalbawy FMA, Mukhlif BAM, Hussen A, Mohammed JS, S RJ, Singh A, et al. Regenerative potential of PRP-based scaffolds in chronic wound healing: Mechanisms, advances, and therapeutic insights. Regen Ther 2025; 30: 278-298.
46. Myung H, Jang H, Myung JK, Lee C, Lee J, Kang J, et al. Platelet-rich plasma improves the therapeutic efficacy of mesenchymal stem cells by enhancing their secretion of angiogenic factors in a combined radiation and wound injury model. Exp Dermatol 2020; 29: 158-167.
47. Rafati F, Ghorbani Z, Manoochehrabadi T, Khosravi F, Majidi J, Eskandari F, et al. Smart integrated biomaterial systems for precision and optimized delivery of MSCs and their exosomes: Transforming wound healing and organ regeneration. Regen Ther 2026; 31: 101045.
48. Nasiri H, Manoochehrabadi T, Eskandari F, Majidi J, Gholipourmalekabadi M. Genetic modification of mesenchymal stem cells (MSCs): Novel strategy to expand their naïve applications in critical illness. Mol Biol Rep 2025; 52: 501.
Iranian Journal of Basic Medical Sciences

Articles in Press, Accepted Manuscript
Available Online from 14 March 2026

Files

Share

How to cite

Statistics